Yankees Showcase $37 Million Pitcher in Spring Training Amid Uncertain Future
Marcus Stroman got his 2025 Spring Training with the New York Yankees back on track. The controversial right-hander was at ...
Arcus Biosciences, Inc. (NYSE:RCUS) Receives $31.29 Average Target Price from Brokerages
Shares of Arcus Biosciences, Inc. (NYSE:RCUS – Get Free Report) have received a consensus recommendation of “Moderate Buy” ...
HC Wainwright Lowers Arcus Biosciences (NYSE:RCUS) Price Target to $18.00
Arcus Biosciences (NYSE:RCUS – Get Free Report) had its price target dropped by equities researchers at HC Wainwright from ...
BioPharma Dive2d
Sanofi reaches consumer health deal; Supernus antidepressant fails study
The pharma signed an agreement handing PE firm CD&R a 50% stake in its Capella unit. Elsewhere, Gilead and Ultragenyx secured ...
Precision BioSciences Touts Encouraging Initial Safety And Antiviral Activity Of Hepatitis B Treatment Candidate
Precision BioSciences reports early PBGENE-HBV trial data showing safety and antiviral activity in chronic Hepatitis B patients, with more results expected in 2025.
BioSpace2d
Gilead Passes on Option for Arcus’ Cancer Drug Despite Strong Early Data
The news comes on the heels of promising Phase I/Ib data, which point to the potential of casdatifan as a more effective ...
Business Wire2d
Precision BioSciences Announces Initial Safety and Antiviral Activity of PBGENE-HBV in the ELIMINATE-B Clinical Trial
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo g ...
Arcus Biosciences price target lowered to $17 from $22 at BofA
BofA lowered the firm’s price target on Arcus Biosciences (RCUS) to $17 from $22 and keeps a Neutral rating on the shares following Gilead’s ...
2RCUS : Arcus Biosciences Shares Are Down Today: What's Going On?
Arcus Biosciences Inc. (NYSE: RCUS) shares are trading lower Tuesday after the company announced a $150 million common stock ...